TriSalus Life SciencesTLSI +3.80%29 Current Ratio is 5.78 as of Mar. 2026, which is 144% above its 10-year median of 2.37. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 82.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. TriSalus Life Sciences's current ratio for the quarter that ended in Mar. 2026 was 5.78.
TriSalus Life Sciences has a current ratio of 5.78. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for TriSalus Life Sciences's Current Ratio or its related term are showing as below:
TLSI'
s Current Ratio Range Over the Past 10 Years
Min: 0.53 Med: 2.37 Max: 5.78
Current: 5.78
During the past 5 years, TriSalus Life Sciences's highest Current Ratio was 5.78. The lowest was 0.53. And the median was 2.37.
TLSI's Current Ratio is ranked better than 82.06% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs TLSI: 5.78
TriSalus Life Sciences (NAS:TLSI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
TriSalus Life Sciences Current Ratio Related Terms
TriSalus Life Sciences Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TriSalus Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Current Ratio of 5.78 as of Mar. 2026. This is 144% above median its historical median of 2.37. Over the past decade, TriSalus Life Sciences' Current Ratio has ranged from 0.53 to 5.78. According to the industry distribution chart, TriSalus Life Sciences ranks #153 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is TriSalus Life Sciences' Current Ratio too high?
TriSalus Life Sciences' current Current Ratio of 5.78 is 144% above median its 10-year median of 2.37. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 5.78. The Medical Devices & Instruments industry median Current Ratio is 2.49. TriSalus Life Sciences' value of 5.78 is 132.1% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #153 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Current Ratio compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #153 out of 853 companies for Current Ratio. This places TriSalus Life Sciences in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. TriSalus Life Sciences' value of 5.78 is 132.1% above this benchmark. Historically, TriSalus Life Sciences' own Current Ratio has ranged from 0.53 to 5.78 over the past decade. While the company's 10-year median is 2.37 vs. the industry median of 2.49, TriSalus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Current Ratio of 5.78 is 132.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Current Ratio is 5.78, which is 144% above median its own 10-year median of 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Current Ratio is 5.78, which is 144% above median its 10-year median of 2.37 and 132.1% above the Medical Devices & Instruments industry median of 2.49. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Current Ratio is 5.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.
Key valuation signals for TLSI:
Current Ratio: 5.78 (144% above median its 10-year median of 2.37)
GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
Industry Position: 132.1% above the Medical Devices & Instruments median (#153 of 853)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
